Healthcare Services

Diagnostic Radioisotopes Market Revenue Expected to Reach $9.26 Billion by 2030 with 8.5% CAGR

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Diagnostic Radioisotopes Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The diagnostic radioisotopes market has seen significant growth in recent years. It is anticipated to increase from $6.08 billion in 2025 to $6.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. This historic growth can be attributed to several factors, including the rising growth in cancer diagnosis rates, the proliferation of nuclear imaging facilities, a continued reliance on technetium-based imaging, the existence of limited isotope production centers, and the prevalence of hospital-based imaging.

The diagnostic radioisotopes market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $9.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This growth during the projection period stems from several factors, including an uptick in demand for oncology imaging, the broadening scope of cardiac nuclear diagnostics, advancements in new radioisotope development, investments in regional isotope production, and the diagnostic requirements of an aging population. Key developments expected in this period encompass the increased utilization of PET and SPECT imaging, a heightened need for oncology radioisotopes, the expansion of nuclear medicine diagnostics, the rising adoption of short-half-life isotopes, and enhancements in radiopharmaceutical supply chains.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16033&type=smp

What Key Drivers Are Influencing The Growth Of The Diagnostic Radioisotopes Market?

The growing prevalence of cancer is anticipated to fuel the expansion of the diagnostic radioisotopes market in the future. Cancer is defined as a condition where abnormal cells multiply uncontrollably, potentially invading nearby tissues and disseminating throughout the body. This increasing worldwide cancer burden stems from demographic changes like an aging and expanding population, alongside increased exposure to risk factors such as tobacco consumption, obesity, and environmental contaminants. In healthcare, diagnostic radioisotopes play a crucial role by facilitating accurate imaging, early identification, and efficient tracking of cancer development or its response to treatment. For example, the National Health Service (NHS), a government health agency in the UK, reported in October 2025 that 354,820 new cancer diagnoses occurred in 2023, averaging 972 cases daily, which marks an increase of 8,605 from 2022. Consequently, the escalating global incidence of cancer is propelling the expansion of the diagnostic radioisotopes market.

What Major Segment Divisions Exist Within The Diagnostic Radioisotopes Market?

The diagnostic radioisotopes market covered in this report is segmented –

1) By Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FluoroDeoxyGlucose (FDG), Rubidium-82, Other Radioisotopes

2) By Imaging Modality: Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Beta Emitters

3) By Application: Oncology, Cardiology, Other Applications

4) By End User: Hospitals, Specialty Clinics, Diagnostic Centers, Academic And Research Institutes, Other End Users

Subsegments:

1) By Technetium-99m: Diagnostic Imaging, Cardiac Imaging, Oncology Imaging, Bone Scans, Renal Scans

2) By Thallium-201: Cardiac Imaging, Myocardial Perfusion Imaging, Stress Tests

3) By Gallium-67: Oncology Imaging (Lymphoma, Tumors), Inflammatory Disease Imaging, Infection Imaging

4) By Iodine-123: Thyroid Imaging, Neurological Imaging (Parkinson’s Disease), Cardiac Imaging

5) By FluoroDeoxyGlucose (FDG): Positron Emission Tomography (PET) Imaging, Cancer Diagnosis And Staging, Neurological Imaging, Cardiac Imaging

6) By Rubidium-82: Cardiac PET Imaging, Myocardial Perfusion Imaging, Coronary Artery Disease Diagnosis

7) By Other Radioisotopes: Strontium-89 (Bone Pain Palliation), Iodine-131 (Thyroid Cancer Treatment), Samarium-153 (Bone Pain Palliation), Yttrium-90 (Cancer Treatment)

How Are Trends Transforming The Diagnostic Radioisotopes Market Landscape?

Companies prominent in the diagnostic radioisotopes market are increasingly adopting advancements like next-generation positron emission tomography (PET) imaging radiotracers to boost diagnostic accuracy, facilitate earlier detection, and improve clinical decision-making. These next-generation PET radiotracers are advanced radioactive imaging agents crafted to target specific molecular or metabolic sites, enabling high-resolution visualization of tumors and metastatic lesions. For example, in July 2024, Radiopharm Theranostics Limited, an Australia-based radiopharmaceutical and theranostics development company, secured US Food and Drug Administration (FDA) Investigational New Drug (IND) approval for F18-Pivalate (RAD 101). This is a Fluorine-18 (F-18) labeled PET imaging agent specifically designed for detecting suspected recurrent brain metastases by targeting Fatty Acid Synthase (FASN), which is overexpressed in solid tumors. The radiotracer is characterized by its high tumor-to-background contrast, favorable imaging kinetics, and compatibility with existing PET systems. F18-Pivalate (RAD 101) thus improves diagnostic precision, supports more accurate identification of metastatic disease, and strengthens clinical decision-making in oncology care.

Which Companies Are Leading Innovation In The Diagnostic Radioisotopes Market?

Major companies operating in the diagnostic radioisotopes market are Cardinal Health Inc., Lantheus Holdings, Curium Pharma, Clarity Pharmaceuticals, Bracco Diagnostic Inc., Nordion Inc., Eckert & Ziegler AG, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd, Cyclopharm Limited, Trasis NV, ARTMS Inc, Radiomedix Inc, Coqu RadioPharmaceuticals Corp, ANSTO, IRE Institute for Radioelements, NRG, China National Nuclear Corporation, Polatom, Niowave Inc, JSC Isotope, Center of Molecular Research, Oak Ridge National Laboratory, SHINE Technologies

Read the full diagnostic radioisotopes market report here:

https://www.thebusinessresearchcompany.com/report/diagnostic-radioisotopes-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Diagnostic Radioisotopes Market?

North America was the largest region in the diagnostic radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diagnostic radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Diagnostic Radioisotopes Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16033&type=smp

Browse Through More Reports Similar to the Global Diagnostic Radioisotopes Market 2026, By The Business Research Company

Nuclear Medicine Radioisotopes Global Market Report

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Urology Medical Lasers Global Market Report

https://www.thebusinessresearchcompany.com/report/urology-medical-lasers-global-market-report

Nuclear Medicine Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795